Assessment of plasmatic cell proliferation and apoptosis indexes in the course of multiple myeloma;Hodnocení proliferačního a apoptotického indexu plazmatických buněk v průběhu mnohoč etného myelomu

Vnitrni Lekarstvi

Volumn 54, Issue 1, 2008, Pages 31-35

  Minařík, Jiří ^a   Scudla V ^a   Ordeltova M ^b   Bacovsky J ^a   Zemanova M ^a   Pika, T ^a  

^a PALACKÝ UNIVERSITY   (Czech Republic)

^b UNIVERSITY HOSPITAL OLOMOUC   (Czech Republic)

Author keywords

Apoptosis index; Multiple myeloma; Myeloma activity; Myeloma plasmocytes; Proliferation index

Indexed keywords

LIPOCORTIN 5;

APOPTOSIS; ARTICLE; CELL PROLIFERATION; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE COURSE; FLOW CYTOMETRY; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; PLASMA CELL; PROGNOSIS; TREATMENT RESPONSE; ADULT; AGED; FEMALE; MALE; MIDDLE AGED; PATHOLOGY;

ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; CELL PROLIFERATION; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PLASMA CELLS; PROGNOSIS;

EID: 39149122839     PISSN: 0042773X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Caligaris-Cappio F. Biology of the malignant plasma cell. In: Wiernik PH, Goldman JM, Dutcher JP et al. Neoplastic Diseases of the Blood. 4th ed. Cambridge: University Press 2003: 58-73.
2. Desikan R, Jagannath S, Richardson P et al. Multiple myeloma and other plasma cell dyscrasias. In: Pazdur R, Coia LR, Hoskins WJ et al (eds). Cancer Management: A Multidisciplinary Approach. 8th ed. Manhasset (NY): CMP Healthcare Media 2004: 727-745.
3. Greipp PR, Kyle RA Staging, Kinetics and Prognosis in Multiple myeloma. In: Wiernik PH, Goldman JM, Dutcher JP et al. Neoplastic Diseases of the Blood. 4th ed. Cambridge: Cambridge University Press 2003: 488-501.
4. Vacca A, Ribatti D, Roncali L et al. Angiogenesis in B Cell Lymphoproliferative Diseases. Biological and Clinical Studies. Leuk Lymphoma 1995; 20: 27-38.
5. Boccadoro M, Gavarotti P, Fossati G et al. Low plasma cell 3(H) thymidine incorporation in monoclonal gammapathy of undetermined significance (MGUS), smoldering myeloma and remission phase myeloma: a reliable indicator of patients not requiring therapy. Brit J Haematol 1984; 58: 689-96.
6. Girino M, Riccardi A, Luoni R et al. Monoclonal antibody Ki-67 as a marker of proliferative activity in monoclonal gammapathies. Acta Haematol 1991; 85: 26-30.
7. Greipp PR, Katzmann JA, O'Fallon M et al. Value of β-2-microglobulin level and plasma cell labeling indices as prognostic factors in patients with newly diagnosed myeloma. Blood 1988; 72: 219-223.
8. San Miguel JF, García-Sanz R Multiple myeloma: differential diagnosis and prognosis. In: Wiernik PH, Goldman JM, Dutcher JP et al. Neoplastic Diseases of the Blood. 4th ed. Cambridge: Cambridge University Press 2003: 179-199.
9. Greipp PR, Kyle RA. Clinical, morphological and cell kinetic differences among multiple myeloma, monoclonal gamma-pathy of undetermined significance, and smoldering multiple myeloma. Blood 1983; 62: 166-171.
10. Joshua D, Petersen A, Brown R et al. The labeling index of primitive plasma cells determines the clinical behaviour of patients with myelomatosis. Brit J Haematol 1996; 94: 76-81.
11. Minařík J, Ščudla V, Ordeltová M et al. Evaluation of plasma cell propidium-iodide and annexin-V indices: their relation to prognosis in multiple myeloma. Biomed Pap 2005: 34: 81-84.
12. Scudla V, Ordeltová M, Bacovsky J et al. The relationship between proliferation and apoptosis in patients with monoclonal gammapathy of undetermined significance or multiple myeloma. Haematologica 2005; 90: 1713-1714.
13. Scudla V, Ordeltova M, Minarik J et al. Prognostic significance of plasma cell propidium iodide and annexin-V indices and their mutual ratio in multiple myeloma. Neoplasma 2006; 53: 199-205.
14. Ščudla V, Ordeltová M, Bačovský J et al. Vyšetření bromdeoxyuridinového indexu u mnohočetného myelomu. I. Vztah k vybraným laboratorním ukazatelům nemoci. Vnitř Lék 1996; 42: 458-463.
15. Ščudla V, Ordeltová M. Vyšetř ení proliferačních charakteristik u mnohoč etného myelomu. II. Vztah ke klinickým a laboratomím ukazatelům nemoci. Hematológia a transfuziológia 1998; 4: 22-28.
16. Witzig TE, Timm M, Larson D et al. Measurement of apoptosis and proliferation of bone marrow plasma cells in patients with plasma cell proliferative disorders. Brit J Haematol 1999; 104: 131-137.
17. Xu JL, Lai R, Kinoshita T et al. Proliferation, apoptosis, and intratumoral vascularity in multiple myeloma: correlation with the clinical stage and cytological grade. J Clin Pathol 2002; 55: 530-534.
18. Maisnar V, Toušková M, Malý J et al. Význam vybraných laboratorních ukazatelů pro diferenciá lní diagnostiku a sledování aktivity mnohoč etného myelomu. Vnitř Lék 2002, 48: 290-297.
19. Fabian P, Křen L, Nenutil R. Assessment of proliferative activity of plasma cells in multiple myeloma. Čes Slov Patol 2004, 39: 46-49.
20. Blade J, Samson D, Reece D et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Brit J Haematol 1998; 102: 1115-1123.
21. Davies FE, Anderson KC. Novel therapeutic targets in multiple myeloma. Eur J Hematol 2000; 64: 359-367.
22. Špička I, Hájek R, Vytřasová M et al. Inhibitor proteazomu - bortezomib (Velcade) - v léčbě refrakterního mnohočetného myelomu. První zkušenosti v České republice. Čas Lék Čes 2005; 144: 636-640.
23. Hájek R, Pour L Bortezomib. Farmakoterapie 2005; 1: 19-21.
24. Greipp PR, Witzig TE, Gonchoroff NJ et al. Immunofluorescence labeling indices in myeloma and related monoclonal gammapathies. Mayo Clin Proc 1987; 62: 969-977.
25. San Miguel JF, Garcia-Sanz R, Gonzales M et al. DNA Cell Content Studies In Multiple Myeloma. Leuk Lymphoma 1996; 23: 33-41.
26. San Miguel JF, Garcia-Sanz R, Gonzales M et al. A New Staging System for Multiple Myeloma Based on the Number of S-Phase Plasma Cells. Blood 1995; 85: 448-455.
27. Greipp PR, Lust JA, O'Fallon WM et al. Plasma cell labeling index and β-2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. Blood 1993; 18: 3382-3387.
28. Durie BGM, Salmon SE, Moon TEP Pretreatment tumor mass, cell kinetics, and prognosis in multiple myeloma. Blood 1980; 55: 364-371.
29. Adam Z, Bednařík J, Neunauer J et al. Mnohoč etný myelom a diferenciální diagnostika bolestí páteře. Doporučení České myelomové skupiny pro včasné vyslovení podezření na mnohočetný myelom a pro včasnou diagnostiku této choroby. Prakt Lék 2006, 86: 396-410.